ESPE Yearbook of Paediatric Endocrinology

Diabetes Care 2018;41:1125–1131. DOI: 10.2337/dc18-er09a)• Many people currently in need of insulin are unable to access it.• Unaffordable price of insulin is a major barrier.• These authors analyse the causes of unsatisfactory access to insulin from a U.S. and global perspective.This article identifies the various ...

To read the full abstract: Diabetes Care. 2017;40:1631-1640[Comments on 10.9 and 10.10] These two publications describe guidelines made by the international learned societies on the use of continuous glucose monitoring devices. It is important to learn from these publications that education and guidance are pivotal before continuous glucose...

J Steroid Biochem Mol Biol. 2020; 200:105684.https://pubmed.ncbi.nlm.nih.gov/32360359/In this mouse cell model, the authors show that metformin appears to directly inhibit signaling of MC2R (the ACTH receptor) and also MC3R.Metformin is used to treat type 2 diabetes and obesity, and may reduce the androgen excess in women with polycystic ovary syndrome (PCOS) or conge...

To read the full abstract: N Engl J Med. 2018 Jun 14;378(24):2275–2287Neurological complications of diabetic ketoacidosis (DKA) are still causes of significant mortality and morbidity in type 1 diabetes (T1D). Children are still being reported with acute cerebral infarction (CI) and extra pontine myelinolysis (EPM) at onset of T1D (1). Frequently, their clinical management had not b...

Brief summary: This commentary discusses the implications of the recent licensing of Teplizumab by the Food and Drug Administration (FDA) as the first immunosuppressant for individuals at risk for type 1 diabetes (T1D).The approval of Teplizumab by the FDA in November 2022, as an intervention to delay the onset of stage 3 T1D (clinical T1D) in adults and children aged 8 or older who have stage 2 T1D (two or more islets autoantibodies and dysglycemia but ...